30 November 2017

Block listing Interim Review

LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, provides the following update on its block listing, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listing arrangements, put in place from 29 July 2016: 

Name of applicant: Verona Pharma plc
Name of scheme: 2016 Warrant Shares
Period of return: From 3 May 2017 to 30 November 2017
Balance of unallotted securities under scheme(s) from previous return: 12,446,370 Ordinary Shares of 5 pence each
Plus: The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for): Nil
Less: Number of securities issued/allotted under scheme(s) during period Nil
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 12,446,370 Ordinary Shares of 5 pence each
Number and class of share(s) (amount of stock/debit securities) originally admitted and the Date of Admission: 10,262,879 on 29 July 2016
 
Name of contact: Claire Poll
Telephone number of contact: +44 (0)20 3283 4200

For further information, please contact:

Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
   
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)
Tel: +44 (0) 20 7710 7600
SNELVeronaPharma@stifel.com
Stewart Wallace / Jonathan Senior / Ben Maddison  

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), and potentially asthma.

Verona Pharma's shares are traded on the London AIM market under the symbol VRP.L. Further information on Verona Pharma can be found at http://www.veronapharma.com/

 

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Victoria Stewart, Director of Communications
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)
Brough Ransom /Mia Gardner (Corporate Broking)
Tel: +44 (0)20 3283 4200

 

 

Optimum Strategic Communications
(European Media and Investor enquiries)
Mary Clark, Annemarieke Ezendam
Hollie Vile
Tel: +44 (0) 203 922 0891
verona@optimumcomms.com

Westwicke, an ICR Company (Investor enquiries)
Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us